肿瘤细胞治疗研究
英文原题：A TCR-like CAR Promotes Sensitive Antigen Recognition and Controlled T-cell Expansion Upon mRNA Vaccination.
A TCR-like CAR Promotes Sensitive Antigen Recognition and Controlled T-cell Expansion Upon mRNA Vaccination.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
嵌合抗原受体（CAR）T 细胞在 B 细胞恶性肿瘤患者中有效，但在实体瘤患者中其活性有限。
嵌合抗原受体（CAR）T细胞对B细胞恶性肿瘤患者有效，但对实体瘤患者活性有限。我们开发了一种新型异源二聚体、类似T细胞受体的CAR（TCAR），旨在实现最佳链配对并整合至T细胞CD3信号复合体。TCAR在短期体外实验中介导了高抗原敏感性和强效抗原特异性T细胞效应功能。提供共刺激信号可增强TCAR T细胞的持续存留和功能，并改善其体内外增殖。联合一种为体内扩增CAR-T 细胞而开发的纳米颗粒RNA疫苗，可促进TCAR T细胞在体内扩增受到严密调控、提高存活并增强抗肿瘤效力。意义：新型TCAR受到RNA疫苗介导的共刺激精密调控，可能成为治疗实体瘤的第二代CAR替代方案。
UNLABELLED: Chimeric antigen receptor (CAR) T cells are efficacious in patients with B-cell malignancies, while their activity is limited in patients with solid tumors. We developed a novel heterodimeric TCR-like CAR (TCAR) designed to achieve optimal chain pairing and integration into the T-cell CD3 signaling complex. The TCAR mediated high antigen sensitivity and potent antigen-specific T-cell effector functions in short-term in vitro assays. Both persistence and functionality of TCAR T cells were augmented by provision of costimulatory signals, which improved proliferation in vitro and in vivo . Combination with a nanoparticulate RNA vaccine, developed for in vivo expansion of CAR T cells, promoted tightly controlled expansion, survival, and antitumor efficacy of TCAR T cells in vivo . SIGNIFICANCE: A novel TCAR is tightly controlled by RNA vaccine-mediated costimulation and may provide an alternative to second-generation CARs for the treatment of solid tumors.
MEMBER ACCOUNT
登录成功会直接打开下一页。
